Peripheral T-cell lymphomas (PTCL) represent a heterogenous group of aggressive non-Hodgkin's lymphoma, with poorer treatment outcomes compared to that of their B-cell counterparts, using conventional chemotherapy^[@CR1]^. Despite the lack of randomized data, upfront high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) has been associated with better treatment outcomes^[@CR2],\ [@CR3]^ and various guidelines now recommend that patients with chemosensitive PTCL should undergo upfront HDC/ASCT^[@CR4]^. Consistently, both retrospective and prospective studies suggest that such a strategy appears to benefit patients with responding disease, especially those in first complete remission (CR1)^[@CR5]^. However, it is conceivable that PTCL patients who do achieve CR1 may have more favorable survival outcomes, regardless of the treatment they received. Thus, we performed a retrospective analysis of PTCL patients who attained CR1 following first-line induction therapy to determine the factors that would impact their survival outcomes, including the role of upfront HDC/ASCT.

Prospectively maintained T-cell lymphoma databases from the National Cancer Centre Singapore (NCCS)/Singapore General Hospital (SGH), Samsung Medical Centre, South Korea, and Sun Yat Sen University Cancer Centre, China, were retrospectively reviewed after approval from the institutional review boards of the individual institutions. We included patients with the following histological subtypes: PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL), and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)^[@CR6],\ [@CR7]^, previously known as type II enteropathic T-cell lymphoma, treated with curative intent. To standardize the effect of treatment on outcome, we excluded patients with ALK-positive ALCL because their first-line treatment would not include considerations for upfront HDC/ASCT^[@CR4]^ and patients with natural-killer/T-cell lymphoma whose treatment may have included upfront allogeneic stem cell transplantation^[@CR8]^. Upfront HDC/ASCT was not standard practice in any of the participating institutions and left to the discretion of the primary physician or tumor board decisions. We also excluded patients with composite lymphomas, cutaneous T-cell lymphomas and patients who were not treated with curative intent. We then reviewed the clinical characteristics, treatment and survival outcomes of patients who achieved CR1. Patients who had partial response, stable disease and progression of disease were excluded from the analysis. Treating physicians determined the end of treatment response assessments. The exact modality was as per institutional standards, which was either computed tomography or positron-emission tomography scans.

Progression-free survival (PFS) was defined as the interval from diagnosis to progression, relapse or death. Overall survival (OS) was defined as the interval from diagnosis to death from any cause. Survival estimates were calculated using the Kaplan−Meier method. Survival curves were compared using the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model to assess the association between several prognostic factors such as age, stage, international prognostic index (IPI)^[@CR9]^, prognostic index for T-cell lymphoma (PIT)^[@CR10]^ and treatment, including the receipt of upfront HDC/ASCT, with survival outcomes. For multivariate analysis, variable selection was performed using the forward selection method, with selection criteria of *P* \< 0.05 for inclusion into the final multivariate model. All variables used in the univariate analysis were entered into the forward selection procedure, except for IPI and PIT scores as the individual components of these scores were already included. Two-sided *p*-values less than 0.05 were considered statistically significant. All analyses were performed in Stata (version 14.2, StataCorp, Texas, USA).

There were 114, 96, and 92 patients respectively in the Singapore, South Korea, and China PTCL database. A total of 175 patients were included in our analysis based on the inclusion and exclusion criteria; 57 from Singapore, 62 from South Korea, and 56 from China, resulting in an overall CR1 rate of 57.9%. Patients in the Singapore cohort were diagnosed between October 1998 and December 2015, patients in the Korean cohort were diagnosed between August 2007 and March 2014, and patients in the Chinese cohort were diagnosed between September 2007 and June 2016.

In this study, the median age was 53 years old, 63% were male and the majority of patients had an ECOG performance status one or less. The most common subtype of PTCL was PTCL-NOS accounting for 42% of the cohort, followed by AITL 33%, ALK negative ALCL 22%, and MEITL 3%. The majority of patients received anthracycline-based chemotherapy and 18% underwent upfront HDC/ASCT. Non-anthracycline-based chemotherapy included ICE (ifosfamide, carboplatin, etoposide) (3%), ESHAP (etoposide, steroids, cytarabine, cisplatin) (1%), Gemcitabine-based regimens (2%), and other regimens (2%) including alemtuzumab-DHAP (steroids, cytarabine, cisplatin) and high-dose methotrexate with procarbazine, and vincristine. In this cohort of patients, the ALK-negative ALCL patients were younger (median age 35 years), they were more likely to have stage I/II disease, normal lactate dehydrogenase (LDH) and less likely to have bone marrow involvement compared to the other subtypes of PTCL in this study. None of the ALK-negative ALCL patients underwent upfront HDC/ASCT (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristics overall and by histological subtypeCharacteristicOverall (*n* = 175)MEITL (*n* = 6)AITL (*n* = 57)PTCL-NOS (*n* = 74)ALK- ALCL (*n* = 38)Age, years Median5361.5575335 Range16--8543--6628--8516--7816--75Age, years (grouped) ≤ 60119 (68)3 (50)34 (60)50 (68)32 (84) \> 6056 (32)3 (50)23 (40)24 (32)6 (16)Sex Female65 (37)2 (33)25 (44)26 (35)12 (32) Male110 (63)4 (67)32 (56)48 (65)26 (68)B symptoms Present76 (43)3 (50)31 (54)29 (39)13 (34) Absent92 (53)2 (33)25 (44)43 (58)22 (58) Unknown7 (4)1 (17)1 (2)2 (3)3 (8)Stage I28 (16)2 (33)3 (5)16 (22)7 (18) II22 (13)1 (17)1 (2)10 (14)10 (26) III57 (33)0 (0)26 (46)19 (26)12 (32) IV61 (35)2 (33)27 (47)27 (36)5 (13) Unknown7 (4)1 (17)0 (0)2 (3)4 (11) I / II50 (29)3 (50)4 (7)26 (35)17 (45) III / IV118 (67)2 (33)53 (93)46 (62)17 (45) Unknown7 (4)1 (17)0 (0)2 (3)4 (11)ECOG performance status 0--1155 (89)5 (83)47 (82)67 (91)36 (95) ≥ 214 (8)0 (0)8 (14)6 (8)0 (0) Unknown6 (3)1 (17)2 (4)1 (1)2 (5)BM involvement Yes31 (18)0 (0)16 (28)14 (19)1 (3) No126 (72)5 (83)41 (72)51 (69)29 (76) Unknown18 (10)1 (17)0 (0)9 (12)8 (21)Extranodal sites 0--1129 (74)4 (67)43 (75)56 (76)26 (68) ≥ 243 (25)1 (17)14 (25)17 (23)11 (29) Unknown3 (2)1 (17)0 (0)1 (1)1 (3)Serum LDH Elevated81 (46)3 (50)37 (65)30 (41)11 (29) Normal84 (48)2 (33)19 (33)38 (51)25 (66) Not evaluated10 (6)1 (17)1 (2)6 (8)2 (5)IPI score Low (0--1)66 (38)2 (33)12 (21)32 (43)20 (53) Low-intermediate (2)44 (25)1 (17)16 (28)19 (26)8 (21) High-intermediate (3)35 (20)1 (17)18 (32)13 (18)3 (8) High (4--5)12 (7)0 (0)8 (14)4 (5)0 (0) Not evaluated18 (10)2 (33)3 (5)6 (8)7 (18)PIT score Low (0)49 (28)2 (33)10 (18)21 (28)16 (42) Low-intermediate (1)55 (31)1 (17)20 (35)25 (34)9 (24) High-intermediate (2)29 (17)1 (17)14 (25)12 (16)2 (5) High (3--4)14 (8)0 (0)10 (18)4 (5)0 (0) Not evaluated28 (16)2 (33)3 (5)12 (16)11 (29)Primary treatment regimen CHOP-like133 (76)3 (50)57 (100)53 (72)20 (53) EPOCH-like28 (16)1 (17)0 (0)10 (14)17 (45) ICE6 (3)1 (17)0 (0)4 (5)1 (3) ESHAP1 (1)0 (0)0 (0)1 (1)0 (0) Gemcitabine-based4 (2)1 (17)0 (0)3 (4)0 (0) Others3 (2)^a^0 (0)0 (0)3 (4)^a^0 (0)Primary treatment regimen (grouped) Anthracycline based161 (92)4 (67)57 (100)63 (85)37 (97) Non-anthracycline based14 (8)2 (33)0 (0)11 (15)1 (3) Others0 (0)0 (0)0 (0)0 (0)0 (0)Auto-SCT Yes32 (18)1 (17)16 (28)15 (20)0 (0) No143 (82)5 (83)41 (72)59 (80)38 (100)^a^alemtuzumab-DHAP; High-dose methotrexate/procarbazine/vincristine

There were several differences between the three cohorts of patients. The Chinese patients were younger (median age 42.5 years), had lower IPI and PIT scores, and they had a significantly higher proportion of patients with ALK-negative ALCL compared to the Singaporean and Korean cohort. With regards to treatment, half of the Chinese patients received EPOCH as first-line therapy while none of the patients in the Singapore and Korean cohort did, and fewer Chinese patients (7%) received upfront HDC/ASCT compared to the Singaporean (28%) and Korean (19%) cohort. Follow-up times in the Singapore, Korean, and Chinese cohort were also significantly different at 6.1 (95% confidence interval (CI), 4.3--7.6), 3.0 (95% CI, 2.2--4.1), and 1.6 (95% CI 1.1--2.0) years respectively.

For the entire cohort, the median OS was not reached and the median PFS was 5.5 years (95% CI, 4.0--8.2 years). The 3-year OS and PFS rates were 89% (95% CI, 82--93%) and 61% (95% CI, 52--68%), respectively and the median follow-up time was 2.7 years (95% CI, 2.2--3.2 years). The 3-year OS for ALK- negative ALCL was 100% compared to 89% (95% CI 76--95%) in PTCL-NOS, 84% (95% CI 70--02%) in AITL, and 80% (20--97%) in MEITL.

On univariate analysis, older age, higher stage, IPI, and PIT scores were significantly associated with a poorer OS. Histological subtypes also significantly correlated with OS on univariate analysis. Age, stage, IPI, and PIT scores, gender and treatment site correlated with PFS on univariate analysis. On multivariate analysis, older age and higher stage were independently prognostic for a poorer OS and older age, male gender and higher stage were independently prognostic for a poorer PFS. Interestingly, there was no evidence that primary treatment, i.e., anthracycline versus non-anthracycline-based treatment or upfront HDC/ASCT correlated with PFS or OS on univariate and multivariate analyses. Even when we considered only patients below 60 years of age, upfront HDC/ASCT did not appear to be associated with a better OS or PFS (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate analyses of overall survival and progression-free survivalVariableOverall survivalProgression-free survivalNo. of events/patientsUnivariate analysisMultivariate analysis^a^No. of events/patientsUnivariate analysisMultivariate analysis^a^Hazard ratio (95% CI)*p*-valueHazard ratio (95% CI)*p*-valueHazard ratio (95% CI)*p*-valueHazard ratio (95% CI)*p*-valueAge, per year^m^24 / 1751.06 (1.02, 1.10)\<0.0011.06 (1.02, 1.10)0.00173 / 1751.02 (1.01, 1.04)0.0021.02 (1.00, 1.04)0.014Age, years ≤ 6010 / 11910.00143 / 11910.036 \> 6014 / 564.17 (1.77, 9.85)30 / 561.68 (1.04, 2.69)Sex^m^ Female6 / 650.46 (0.18, 1.15)0.078Not significant19 / 650.43 (0.26, 0.73)0.0010.48 (0.26, 0.89)0.015 Male18 / 110154 / 11011Stage I1 / 280.12 (0.02, 0.94)0.0345 / 280.24 (0.09, 0.61)0.003 II2 / 220.47 (0.10, 2.10)6 / 220.47 (0.19, 1.13) III9 / 571.04 (0.43, 2.51)25 / 570.89 (0.52, 1.51) IV12 / 61131 / 611Stage (grouped)^m^ I / II3 / 500.24 (0.07, 0.80)0.0070.19 (0.04, 0.87)0.01011 / 500.34 (0.18, 0.66)\<0.0010.31 (0.14, 0.71)0.002 III / IV21 / 1181156 / 11811ECOG performance status^m^ 0--118 / 15510.070Not significant62 / 15510.515Not significant ≥ 25 / 142.76 (1.02, 7.47)8 / 141.29 (0.62, 2.70)BM involvement^m^ Yes9 / 312.02 (0.87, 4.71)0.116Not significant18 / 311.52 (0.88, 2.64)0.147Not significant No14 / 126144 / 1261Extranodal sites^m^ 0--117 / 12910.428Not significant50 / 12910.331Not significant ≥ 27 / 431.44 (0.60, 3.49)20 / 431.30 (0.77, 2.18)Serum LDH^m^ Elevated16 / 811.97 (0.84, 4.61)0.109Not significant40 / 811.56 (0.95, 2.56)0.077Not significant Normal8 / 84126 / 841 Histological subtype^m^ MEITL2 / 61.88 (0.40, 8.84)0.018Not significant5 / 61.89 (0.73, 4.88)0.531Not significant AITL13 / 571.72 (0.73, 4.02)26 / 570.95 (0.56, 1.61) PTCL-NOS9 / 74131 / 741 ALK-negative ALCL0 / 38NE (no events)11 / 380.81 (0.40, 1.62)IPI score Low (0--1)5 / 6610.02317 / 6610.024 Low-intermediate (2)7 / 442.37 (0.75, 7.51)19 / 441.97 (1.02, 3.79) High-intermediate (3)6 / 353.07 (0.93, 10.16)18 / 352.31 (1.18, 4.49) High (4--5)5 / 127.45 (2.08, 26.62)8 / 122.89 (1.24, 6.72)PIT score Low (0)2 / 4910.01010 / 4910.027 Low-intermediate (1)9 / 554.53 (0.97, 21.15)24 / 552.40 (1.15, 5.03) High-intermediate (2)5 / 294.75 (0.92, 24.58)15 / 292.76 (1.24, 6.17) High (3--4)6 / 1411.64 (2.31, 58.69)8 / 142.88 (1.13, 7.33)Primary treatment regimen^m^ Anthracycline based22 / 16110.801Not significant68 / 16110.479Not significant Non-anthracycline based2 / 140.83 (0.20, 3.56)5 / 140.73 (0.29, 1.81)Autologous SCT^m^ Yes3 / 320.41 (0.12, 1.38)0.110Not significant16 / 320.99 (0.56, 1.74)0.972Not significant No21 / 143157 / 1431Autologous SCT in young patients only (≤60 years) Yes2 / 290.57 (0.12, 2.72)0.45714 / 291.39 (0.73, 2.65)0.324 No8 / 90129 / 901^a^ Final multivariable model after application of variable selection procedure. Variables used in the selection procedure are marked^m^Note that non-proportional hazards were detected for age and stage (grouped) in univariate analysis for PFS*AITL* angioimmunoblastic T-cell lymphoma, *ALCL* anaplastic large cell lymphoma, *ALK* anaplastic lymphoma kinase, *BM* bone marrow, *CI* confidence interval, *MEITL* monomorphic epitheliotropic intestinal T-cell lymphoma, *ECOG* Eastern Cooperative Oncology Group, *IPI* International Prognostic Index, *LDH* lactate dehydrogenase, *NA* not applicable, *NE* not evaluable, *OS* overall survival, *PFS* progression-free survival, *PIT* Prognostic Index for T-cell lymphoma, *PTCL-NOS* peripheral T-cell lymphoma, not otherwise specified, *SCT* stem-cell transplantation

We further analyzed the data excluding patients with ALK-negative ALCL since they were a low-risk population that did not undergo upfront HDC/ASCT in this study and found that an older age, male gender, advanced stage, higher PIT scores, and upfront HDC/ASCT were associated with a poorer OS on univariate analysis. However, on multivariate analysis, only age and gender were significantly associated with a poorer OS. Excluding the ALK-negative cohort, advanced age, male gender, advanced stage, elevated LDH, higher IPI, and PIT scores were associated with a poorer PFS on univariate analysis but only male gender and advanced stage were significantly associated with a poorer PFS on multivariate analysis. We also performed an analysis excluding the Chinese cohort of patients as they appeared to have a cohort of patients with more favorable parameters including a younger age, lower IPI, and PIT scores and fewer Chinese patients received upfront HDC/ASCT. In this analysis, a higher age, stage, PIT scores, and the male gender were associated with a poorer OS on univariate analysis and only a higher age and stage were significantly associated with a poorer OS on multivariate analysis. Excluding the Chinese cohort, a higher age and stage, and the male gender were associated with a poorer PFS on both univariate and multivariate analyses.

The retrospective nature of this study means patient and treatment factors, such as first-line chemotherapy regimens, are not standardized. Data on dose intensity and density are also limited. Although most of the histological diagnoses were made by hematopathologists at tertiary academic centers, there was no central review and diagnoses were made according to the World Health Organization (WHO) guidelines, which have undergone changes over the years. Small numbers of patients also limits the subgroup analysis and the manner in which end of treatment assessments were performed was variable according to institutional standards. Nonetheless, given the rarity of this disease, this study provides valuable information from large and longitudinal data sets from three major academic centers in Asia and it reflects real-world experience.

In conclusion, our study shows that patients with PTCL who do achieve CR1 may have a better prognosis than their contemporaries who do not achieve CR1. Similar to other reports^[@CR11]--[@CR13]^, the use of HDC/ASCT in our study did not appear to improve PFS or OS. Prospective trials are needed to validate this observation.
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